poisar

Stock

Rhythm Pharmaceuticals, Inc. RYTM

$109.94+1.03%

Overview

RYTM market data

Price History

RYTM price chart · 1M
O
108.19
H
112.00
L
108.19
C
109.94
Vol
31,855.00
Source
US equities market feed
Observed
Aug 21, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$108.19
Previous Close
$108.82
Day High
$112.00
Day Low
$108.19
52 Week High
$119.66
52 Week Low
$74.50
7 Day Return
-4.71%
30 Day Return
+5.72%
90 Day Return
+22.37%
1 Year Return
+22.76%
Daily Notional Volume
$3.5M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.02
Diluted earnings per share over the trailing twelve months.
Beta
2.00
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-85.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$74.50 – $122.20
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $8.1B · P/B 26.45 · P/S 33.92.

Company News

10 captured
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic ObesityBenzinga · Aug 24, 2026, 1:28 PM
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?Benzinga · Aug 12, 2026, 5:18 PM
Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug DesignationBenzinga · Aug 11, 2026, 12:03 PM
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146Benzinga · Aug 7, 2026, 4:44 PM
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143Benzinga · Aug 5, 2026, 7:20 PM
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155Benzinga · Aug 5, 2026, 5:06 PM
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160Benzinga · Aug 5, 2026, 3:11 PM
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings CallBenzinga · Aug 4, 2026, 1:33 PM
8-K filing — RHYTHM PHARMACEUTICALS, INC. (RYTM)SEC EDGAR · Aug 4, 2026, 11:49 AM
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic ObesityGlobenewswire Inc · Aug 4, 2026, 11:15 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock